A Multicenter, Global, Randomized, Double-Blind Study Of Axitinib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced Hepatocellular Carcinoma Following Failure Of One Prior Antiangiogenic Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Overall Survival
2 years
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A4061058
NCT01210495
December 2010
January 2014
Name | Location |
---|---|
H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida 33612 |
Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada 89109 |
Methodist Estabrook Cancer Center | Omaha, Nebraska 68114-4199 |
Moores UCSD Cancer Center | La Jolla, California 92093-0658 |
Alta Bates Summit Comprehensive Cancer Center | Berkeley, California 94704 |
Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
University of California Irvine Medical Center | Orange, California 92668 |
UCSD Medical Center- La Jolla | La Jolla, California 92037 |
Ship Drugs to: | Orange, California 92868 |
UCSD Medical Center- Hillcrest | San Diego, California 92103 |
Penn Presbyterian Medical Center | Philadelphia, Pennsylvania 19104-2699 |
Florida Hospital Orlando | Orlando, Florida 32804 |
A. Alfred Taubman Health Care Center | Ann Arbor, Michigan 48109 |